ShiveringPhase 4NCT03679065
Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering
A Phase 4 study testing Paracetamol and Dexamethasone in people with Shivering, run by Ain Shams University at 1 site in Egypt.
Trial summary
This study was conducted to evaluate the effects of a prophylactic dose of oral paracetamol on shivering compared with prophylactic intravenous infusion (IVI) dexamethasone in patients undergoing non-obstetric surgeries under spinal anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Shivering
- What is being tested?
- Paracetamol and Dexamethasone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Mar 2018to 31 Aug 2018
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- • on 300 patients aged 18-60 years
- of the American Society of Anesthesiologists (ASA) physical status I or II
- underwent non-obstetric surgeries under spinal anesthesia. A written informed consent was obtained from all patients to participate in the study.
Who cannot join
- • Patient's refusal,
- duration of surgery more than 120 min,
- obesity with body mass index (BMI) >35 kg/m2,
- generalized infection or localized infection at level of blockade,
- neurologic disease,
- coagulation disorder,
Show all 13Show fewer
- patients with hypo- or hyperthyroidism,
- cardiopulmonary disease,
- psychological disorders,
- a need for blood transfusion during surgery,
- an initial body temperature >38.0C or <36.0C,
- a known history of alcohol or substance abuse,
- or receiving vasodilators, or medications likely to alter thermoregulation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Non-obstetric Surgeries: a Randomized Controlled Trial
This study was conducted to evaluate the effects of a prophylactic dose of oral paracetamol on shivering compared with prophylactic intravenous infusion (IVI) dexamethasone in patients undergoing non-obstetric surgeries under spinal anesthesia.
Read the detailed description
Enrollment After approval by the institute ethics committee, this study was conducted at Ain-Shams university hospitals, from the1st of March 2018 till the 31st of August 2018, on 300 patients aged 18-60 years and body weight 60-100 Kg of the American Society of Anesthesiologists (ASA) physical status I or II who underwent non-obstetric surgeries under spinal anesthesia were enrolled in this study.
Patient's refusal, duration of surgery more than 120 min, obesity with body mass index (BMI) >35 kg/m2, generalized infection or localized infection at level of blockade, neurologic disease, coagulation disorder, patients with hypo- or hyperthyroidism, cardiopulmonary disease, psychological disorders, a need for blood transfusion during surgery, an initial body temperature >38.0C or <36.0C, a known history of alcohol or substance abuse, or receiving vasodilators, or medications likely to alter thermoregulation excluded the patient. from the study Randomization and Blinding This study was designed to be a randomized, placebo-controlled, double-blinded parallel study. Following enrollment, patients were randomized into 3 equal groups;
- The P (Paracetamol) group:(n=100) each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
- The D (Dexamethasone) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
- The C (Control) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Randomization was done using computer-generated table of random numbers in a 1:1 ratio in opaque and sealed envelope (SNOSE). The assigned treatment was written on a card and sealed in opaque envelopes consecutively numbered. These envelopes were opened just immediately before infusing the medication in the patient's room. The study drugs were prepared by the hospital pharmacy and follow-up of patients were conducted by anesthesia residents not involved in any other part of the study.
Study Protocol On arrival in the operating theatre, all patients had an inserted venous cannula. I.V. fluids were preheated to 37oC. No other warming device was used. Lactated Ringer's solution was warmed to 37 oC and was infused at 10 ml/kg over 30 min before spinal anesthesia. The infusion rate was reduced to 6 ml/ kg.
Subarachnoid anesthesia was instituted at either L3/4 or L4/5 interspaces. Hyperbaric bupivacaine, 5 mg /ml, 15 mg was injected using a 25 G Quincke spinal needle.
Supplemental oxygen (5 liter/ min) was delivered via a facemask during the operation. All patients were covered with one layer of surgical drapes over the chest, thighs, and calves during the operation and one cotton blanket over the entire body after operation. The operating and recovery rooms temperatures were maintained at 23-25°C with approximately 60% humidity.
Assessment parameters Heart rate, mean arterial pressure (MAP), and peripheral oxygen saturation were recorded using standard noninvasive monitors before intrathecal injection and thereafter at 5, 10, 15, 20 minutes then every 10 minutes to complete 90 minutes from the intrathecal injection.
Sensory levels were assessed by pinprick to determine the peak sensory level and time to two segment regression in minutes. Motor block was assessed by using Modified Bromage scale(16) (0 = no block 1 = hip block, 2 = hip and knee block, 3 = hip, knee, and ankle block) to determine the time to reach complete motor block and duration of motor blockade (minutes).
Sedation score was assessed with a four-point scale as per Filos et al.(17): 1: Awake and alert. 2: Somnolent, but responsive to verbal stimuli. 3: Somnolent, arousable to physical stimuli. 4: Unarousable.
Body temperature (axillary temperature) was recorded with an axillary thermometer. The ambient temperature was measured by a wall thermometer. The ambient temperature was maintained at 25oC with constant humidity.
Shivering if occurred was graded using a scale similar to that validated by Badjatia et al (18):
- None: no shivering noted on palpation of the masseter, neck, or chest wall
- Mild: shivering localized to the neck and/or thorax only
- Moderate: shivering involved gross movement of the upper extremities (in addition to neck and thorax)
- Severe: shivering involved gross movements of the trunk and upper and lower extremities.
Shivering was assessed immediately before the block and every 10 minutes till the end of surgery and for another 20 min in the recovery room. Grade 3 or 4 of shivering score was regarded failure of prophylaxis, meperidine 25 mg IV was administered and no assessment of shivering was done.
Side-effects, including hypotension (defined as a decrease in MAP of more than 20% from baseline or a decrease of arterial blood pressure below 90 mmHg and baseline MAP was calculated from three measurements taken on the ward before surgery) was treated by crystalloid infusion and if necessary ephedrine 5 mg IV was administered. The amount of ephedrine given in each group was recorded. Bradycardia was considered if the heart rate <50 beats/min and was treated with IV atropine (0.01mg/kg). If there was respiratory depression (RR < 12 bpm) and a decrease in arterial SpO2 (<90%), it was treated with oxygen through a transparent face mask. Incidence of nausea and vomiting during early 2 hours postoperatively were recorded. IV granisetron (1 mg) was given in case of vomiting or after 2 successive episodes of nausea.
Patient's satisfaction was done by asking the patient to answer the question, "How would you rate your experience after the surgery?" using a 7-point Likert verbal rating scale(19): [Figure 1] and acceptable satisfaction score of the patient being 5-7.
Likert scale:
1 2 3 4 5 6 7 Extremely dissatisfied Dissatisfied Somewhat dissatisfied Undecided Somewhat satisfied Satisfied Extremely satisfied Figure 1: A 7-point Likert-like verbal rating scale for assessment of patients' satisfaction(19).
Endpoint: The study end point was 20 minutes after the end of the procedure (in the recovery room)
Primary Outcome Measure:
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Secondary Outcome Measures:
- Incidence, onset, severity and duration of post-spinal shivering.
- Time to first analgesic request, from the end of surgery up to approximately six hours after surgery
- Incidence of hypotension.
- Incidence of bradycardia.
- Incidence of nausea and vomiting during early 2 hours postoperatively.
- Patient' satisfaction towards shivering prophylaxis was assessed 24 hours after the procedure. 3-Analysis of Data:
Depending on Gholami et al., 2016 who found that shivering was 18% and 64.0% in paracetamol and control respectively(20) and on El Bakry et al., 2016 who found that shivering was 20.0% and 50.0% in dexamethasone and control respectively(21) and assuming the power= 0.80 and α=0.05, and by using PASS 11th release the minimal sample size for an equal controlled study to detect a significant statistical difference between paracetamol \& dexamethasone and control was 80 women in each group. We recruited 100 women in each group for possible attrition(22).
The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013.
- Conditions
- Shivering
- Being tested
- Paracetamol, Dexamethasone, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParacetamolDrug
Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
DexamethasoneDrug
Also called Dexamethasone phosphate
Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
PlaceboDrug
Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
| Study group | Role | What they receive |
|---|---|---|
| P (Paracetamol) group:(n=100) | Active comparator | Not described Receives: Drug: Paracetamol |
| D (Dexamethasone) (Dex) group: (n=100) | Active comparator | Not described Receives: Drug: Dexamethasone |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Measured: Till 20 minutes after the end of the procedure (in the recovery room)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2018
- Study start1 Mar 2018
- Primary completion31 Aug 2018
- Study completion31 Aug 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ShiveringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr.Ibrahim Mamdouh Esmat, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03679065
- Sponsor's protocol ID
- R 49 / 2018
- Status last verified
- Sep 2018
- First submitted
- 19 Sep 2018
- Last updated
- 20 Sep 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Esmat IM, Mohamed MM, Abdelaal WA, El-Hariri HM, Ashoor TM. Postspinal anesthesia shivering in lower abdominal and lower limb surgeries: a randomized controlled comparison between paracetamol and dexamethasone. BMC Anesthesiol. 2021 Oct 30;21(1):262. doi: 10.1186/s12871-021-01483-7.
PubMed 34717535
Study at a glance
From the registry record, last updated by the sponsor on 20 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Non-obstetric Surgeries: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03679065
- Acronym / sponsor ID
- R 49 / 2018
- Conditions
- Shivering
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Mar 2018 (actual)
- Primary completion
- 31 Aug 2018 (actual)
- Study completion
- 31 Aug 2018 (actual)
- First posted
- 20 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was conducted to evaluate the effects of a prophylactic dose of oral paracetamol on shivering compared with prophylactic intravenous infusion (IVI) dexamethasone in patients undergoing non-obstetric surgeries under spinal anesthesia.
Detailed description
Enrollment After approval by the institute ethics committee, this study was conducted at Ain-Shams university hospitals, from the1st of March 2018 till the 31st of August 2018, on 300 patients aged 18-60 years and body weight 60-100 Kg of the American Society of Anesthesiologists (ASA) physical status I or II who underwent non-obstetric surgeries under spinal anesthesia were enrolled in this study.
Patient's refusal, duration of surgery more than 120 min, obesity with body mass index (BMI) >35 kg/m2, generalized infection or localized infection at level of blockade, neurologic disease, coagulation disorder, patients with hypo- or hyperthyroidism, cardiopulmonary disease, psychological disorders, a need for blood transfusion during surgery, an initial body temperature >38.0C or <36.0C, a known history of alcohol or substance abuse, or receiving vasodilators, or medications likely to alter thermoregulation excluded the patient. from the study Randomization and Blinding This study was designed to be a randomized, placebo-controlled, double-blinded parallel study. Following enrollment, patients were randomized into 3 equal groups;
- The P (Paracetamol) group:(n=100) each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
- The D (Dexamethasone) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
- The C (Control) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Randomization was done using computer-generated table of random numbers in a 1:1 ratio in opaque and sealed envelope (SNOSE). The assigned treatment was written on a card and sealed in opaque envelopes consecutively numbered. These envelopes were opened just immediately before infusing the medication in the patient's room. The study drugs were prepared by the hospital pharmacy and follow-up of patients were conducted by anesthesia residents not involved in any other part of the study.
Study Protocol On arrival in the operating theatre, all patients had an inserted venous cannula. I.V. fluids were preheated to 37oC. No other warming device was used. Lactated Ringer's solution was warmed to 37 oC and was infused at 10 ml/kg over 30 min before spinal anesthesia. The infusion rate was reduced to 6 ml/ kg.
Subarachnoid anesthesia was instituted at either L3/4 or L4/5 interspaces. Hyperbaric bupivacaine, 5 mg /ml, 15 mg was injected using a 25 G Quincke spinal needle.
Supplemental oxygen (5 liter/ min) was delivered via a facemask during the operation. All patients were covered with one layer of surgical drapes over the chest, thighs, and calves during the operation and one cotton blanket over the entire body after operation. The operating and recovery rooms temperatures were maintained at 23-25°C with approximately 60% humidity.
Assessment parameters Heart rate, mean arterial pressure (MAP), and peripheral oxygen saturation were recorded using standard noninvasive monitors before intrathecal injection and thereafter at 5, 10, 15, 20 minutes then every 10 minutes to complete 90 minutes from the intrathecal injection.
Sensory levels were assessed by pinprick to determine the peak sensory level and time to two segment regression in minutes. Motor block was assessed by using Modified Bromage scale(16) (0 = no block 1 = hip block, 2 = hip and knee block, 3 = hip, knee, and ankle block) to determine the time to reach complete motor block and duration of motor blockade (minutes).
Sedation score was assessed with a four-point scale as per Filos et al.(17): 1: Awake and alert. 2: Somnolent, but responsive to verbal stimuli. 3: Somnolent, arousable to physical stimuli. 4: Unarousable.
Body temperature (axillary temperature) was recorded with an axillary thermometer. The ambient temperature was measured by a wall thermometer. The ambient temperature was maintained at 25oC with constant humidity.
Shivering if occurred was graded using a scale similar to that validated by Badjatia et al (18):
- None: no shivering noted on palpation of the masseter, neck, or chest wall
- Mild: shivering localized to the neck and/or thorax only
- Moderate: shivering involved gross movement of the upper extremities (in addition to neck and thorax)
- Severe: shivering involved gross movements of the trunk and upper and lower extremities.
Shivering was assessed immediately before the block and every 10 minutes till the end of surgery and for another 20 min in the recovery room. Grade 3 or 4 of shivering score was regarded failure of prophylaxis, meperidine 25 mg IV was administered and no assessment of shivering was done.
Side-effects, including hypotension (defined as a decrease in MAP of more than 20% from baseline or a decrease of arterial blood pressure below 90 mmHg and baseline MAP was calculated from three measurements taken on the ward before surgery) was treated by crystalloid infusion and if necessary ephedrine 5 mg IV was administered. The amount of ephedrine given in each group was recorded. Bradycardia was considered if the heart rate <50 beats/min and was treated with IV atropine (0.01mg/kg). If there was respiratory depression (RR < 12 bpm) and a decrease in arterial SpO2 (<90%), it was treated with oxygen through a transparent face mask. Incidence of nausea and vomiting during early 2 hours postoperatively were recorded. IV granisetron (1 mg) was given in case of vomiting or after 2 successive episodes of nausea.
Patient's satisfaction was done by asking the patient to answer the question, "How would you rate your experience after the surgery?" using a 7-point Likert verbal rating scale(19): [Figure 1] and acceptable satisfaction score of the patient being 5-7.
Likert scale:
1 2 3 4 5 6 7 Extremely dissatisfied Dissatisfied Somewhat dissatisfied Undecided Somewhat satisfied Satisfied Extremely satisfied Figure 1: A 7-point Likert-like verbal rating scale for assessment of patients' satisfaction(19).
Endpoint: The study end point was 20 minutes after the end of the procedure (in the recovery room)
Primary Outcome Measure:
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Secondary Outcome Measures:
- Incidence, onset, severity and duration of post-spinal shivering.
- Time to first analgesic request, from the end of surgery up to approximately six hours after surgery
- Incidence of hypotension.
- Incidence of bradycardia.
- Incidence of nausea and vomiting during early 2 hours postoperatively.
- Patient' satisfaction towards shivering prophylaxis was assessed 24 hours after the procedure. 3-Analysis of Data:
Depending on Gholami et al., 2016 who found that shivering was 18% and 64.0% in paracetamol and control respectively(20) and on El Bakry et al., 2016 who found that shivering was 20.0% and 50.0% in dexamethasone and control respectively(21) and assuming the power= 0.80 and α=0.05, and by using PASS 11th release the minimal sample size for an equal controlled study to detect a significant statistical difference between paracetamol \& dexamethasone and control was 80 women in each group. We recruited 100 women in each group for possible attrition(22).
The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| P (Paracetamol) group:(n=100) | Active comparator | Drug: Paracetamol |
| D (Dexamethasone) (Dex) group: (n=100) | Active comparator | Drug: Dexamethasone |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- • on 300 patients aged 18-60 years
Key exclusion criteria (13 listed)
- • Patient's refusal,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ParacetamolEach patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively. | Drug | P (Paracetamol) group:(n=100) |
| DexamethasoneAlso: Dexamethasone phosphateEach patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively. | Drug | D (Dexamethasone) (Dex) group: (n=100) |
| PlaceboEach patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively. | Drug | Placebo |
Primary outcome
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Time frame: Till 20 minutes after the end of the procedure (in the recovery room)
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Sep 2018.
- Derived from this study: PubMed 34717535Esmat IM, Mohamed MM, Abdelaal WA, El-Hariri HM, Ashoor TM. Postspinal anesthesia shivering in lower abdominal and lower limb surgeries: a randomized controlled comparison between paracetamol and dexamethasone. BMC Anesthesiol. 2021 Oct 30;21(1):262. doi: 10.1186/s12871-021-01483-7.
Related trials for Shivering
Recruiting
Effect Of Acupressure On Hypothermıa And Shıverıng After Cesarean Sectıon
Hypothermia, Shivering
Not yet recruitingPhase 4
Intravenous Paracetamol Versus Magnesium Sulfate for Control of Shivering Following Spinal Anesthesia in Cesarean Section
Shivering, Post-Spinal Shivering
Not yet recruitingPhase 4
Optimizing the Paracetamol Dose for Prevention of Post-Spinal Shivering in Lower Limb Orthopedic Surgeries
Shivering, Postoperative Shivering
Not yet recruitingPhase 4
Efficacy of Intravenous Midazolam-Ketamine Combination Versus Placebo for Prevention of Post-Spinal Shivering in Elective Cesarean Section
Shivering, Post-Spinal Shivering
Not yet recruitingPhase 4
Effect of Preoperative Intranasal Dexmedetomidine on Incidence of Intraoperative Shivering in Patients Undergoing Cesarean Section Under Spinal Anesthesia
Shivering, Hypothermia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Paracetamol and Dexamethasone in people with Shivering, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room) (time frame: Till 20 minutes after the end of the procedure (in the recovery room)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03679065, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2018.